Medtronic Posts Strong Q1 FY2027 Earnings Despite Year-To-Date Stock Underperformance
Medtronic reported impressive financial results for its first quarter of fiscal year 2027, ending July 31. Revenue grew 13.7% year-over-year to $9.8 billion, while adjusted earnings per share (EPS) rose 15.1% to $1.45, both surpassing market expectations. The company raised its full-year revenue and EPS guidance in response. Despite this, Medtronic’s stock price has declined approximately 2% since the start of the year, underperforming the S&P 500’s 12% gain over the same period. This disparity suggests a potential buying opportunity for long-term investors.
Medtronic’s cardiac ablation therapies were a standout contributor, with revenue in this segment soaring 88% year-over-year during the quarter. Looking ahead, the Hugo robotic-assisted surgery system is anticipated to boost market penetration and drive further growth. Additionally, Medtronic plans to spin off its diabetes care division, which currently has a lower operating margin; this restructuring could enhance overall profitability. Having increased dividends for 49 consecutive years, Medtronic is nearing inclusion in the elite “Dividend Kings” group, appealing to investors seeking steady income streams.
MercadoLibre's Aggressive Expansion Pressures Margins but Revenue Growth Remains Robust
MercadoLibre, a leading Latin American e-commerce and fintech company, is currently investing heavily to fend off intensifying competition, impacting short-term profitability. The company expanded its free shipping program and accelerated the rollout of financial services, including credit card offerings. These initiatives have increased provisions for expected credit losses, limiting net profit growth in the near term.
Nonetheless, MercadoLibre’s second-quarter revenue surged nearly 50% year-over-year, reaching $10.2 billion. EPS declined from $10.31 in the prior year quarter to $9.19 this period. Despite the profit pressure, MercadoLibre’s investment in free shipping and financial services mirrors strategies successfully executed by other e-commerce firms, which have historically led to significant growth in gross merchandise volume and overall income. Early financial results reflect these positive developments.
MercadoLibre’s large ecosystem of users and sellers generates strong network effects and high switching costs, reinforcing its competitive moat. Furthermore, Latin America’s low current financial penetration offers substantial room for expansion in e-commerce and digital financial products, which are poised to sustain long-term growth. The stock has retreated about 18% over the past year, presenting a potential entry point for investors focused on market opportunity and business scale.
Investment Implications for Long-Term Portfolios
Both Medtronic and MercadoLibre face distinct challenges—Medtronic contends with a cautious stock market environment, while MercadoLibre navigates short-term margin pressures amid accelerated expansion. However, each maintains a leading market position, clear growth trajectories, and the potential for improving financial metrics. They represent compelling options for investors prioritizing sustainable growth and dividend income over extended horizons.